Clinical-stage biopharmaceutical company leveraging AI to develop neuroscience and oncology therapies.
BioXcel Therapeutics, Inc. is a pioneering biopharmaceutical company at the forefront of leveraging artificial intelligence to revolutionize medicine across neuroscience and immuno-oncology. Founded in 2017 and based in New Haven, Connecticut, the company applies innovative AI-driven approaches to enhance existing drugs and clinically validated candidates. By integrating big data analytics with proprietary machine learning algorithms, BioXcel identifies novel therapeutic opportunities to address unmet medical needs.
One of BioXcel's key achievements is IGALMI (BXCL501), a proprietary sublingual film formulation of dexmedetomidine. This innovative product is aimed at the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Beyond its commercial success, BioXcel is actively advancing BXCL501 through clinical trials. These trials explore its potential application in Alzheimer's disease, major depressive disorder, and other psychiatric conditions, further underscoring its commitment to broadening treatment options.
In addition to BXCL501, BioXcel is advancing BXCL502, designed as a therapy for chronic agitation in dementia patients. This initiative reflects the company's dedication to expanding its neurology-focused portfolio. Furthermore, BioXcel is pioneering BXCL701, an investigational orally administered systemic innate immunity activator. BXCL701 is targeted for aggressive forms of prostate cancer and advvanced solid tumors that are refractory to checkpoint inhibitors, illustrating the company's innovative approach in immuno-oncology.
BioXcel Therapeutics, Inc. continues to push the boundaries of biomedical innovation through its AI-driven drug re-innovation strategy. By transforming scientific insights into therapeutic solutions, the company aims to make significant contributions to patient care and medical advancement worldwide.